A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Albuterol (Albuterol)

Albuterol Sulfate HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airwa....

First FDA approval1989-12-05
Generic availableYes · 25 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$1.05B in CY2024 Part D spend32.4M claims · 13.3M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.032/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.060
Across all dosage forms in distribution.
Highest NADAC
$0.065
Range is tight.
Plans with PA
1307 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Albuterol used for?

Albuterol Sulfate HFA is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airwa....

Is there a generic for Albuterol?

Yes. 40 ANDAs filed at FDA, 25 generic manufacturers currently shipping.

How much does my plan pay for Albuterol?

Across 329 Part D plans, Albuterol averages $0.060/unit (NADAC). Lowest available: $0.032/unit. Highest in distribution: $0.065/unit.

Is Albuterol on the FDA shortage list?

Yes. Albuterol is currently listed as an active FDA shortage.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.